Related Experiment Video
Updated: Jul 31, 2026
Orthotopic Aortic Transplantation: A Rat Model to Study the Development of Chronic Vasculopathy
Published on: December 4, 2010
Transplant Coronary Vasculopathy
1Rush Heart Failure and Cardiac Transplant Program, Rush Presbyterian St. Luke's Medical Center, 1725 West Harrison Street Suite 439PB, Chicago, IL 60612-3824, USA.
Insights
Transplant coronary vasculopathy, a complication of heart transplantation, often presents with severe symptoms. Early detection and risk factor modification are crucial for managing this condition.
Area of Science:
- Cardiology
- Transplantation Immunology
Background:
- The transplanted heart is denervated, meaning classic angina is rarely a symptom of allograft coronary vasculopathy.
- Symptoms like decreased exercise capacity, shortness of breath, or syncope warrant thorough assessment in cardiac transplant recipients.
- Acute myocardial infarction, heart failure, or sudden death can be the initial presentation of transplant vasculopathy.
Purpose of the Study:
- To highlight the importance of annual evaluations for transplant coronary vasculopathy.
- To discuss diagnostic modalities for detecting early signs of vasculopathy.
- To outline preventive and treatment strategies for managing transplant coronary vasculopathy.
Main Methods:
- Annual patient evaluations are recommended for transplant coronary vasculopathy.
- Coronary angiography, while standard, is insensitive for early detection.
- Intracoronary ultrasound in conjunction with angiography identifies intimal thickening, an early sign of vasculopathy.
- Dobutamine echocardiography assesses ischemic burden in patients with diagnosed vasculopathy.
Main Results:
- Transplant coronary vasculopathy is characterized by intimal thickening due to smooth muscle cell proliferation, leading to luminal narrowing.
- Early detection is critical as symptoms can be severe and include acute myocardial infarction or sudden death.
- Preventive measures involve aggressive management of traditional coronary risk factors.
Conclusions:
- Annual screening and prompt assessment for symptoms are vital in heart transplant recipients.
- Intracoronary ultrasound offers improved sensitivity for early transplant coronary vasculopathy detection.
- Management focuses on risk factor modification, with limited treatment options once vasculopathy is established, making retransplantation the only definitive therapy.
Abstract:
Because the transplanted heart is denervated, classic angina as a symptom of allograft coronary vasculopathy rarely is perceived. Any cardiac transplant patients who presents with decreased exercise capacity, shortness of breath, or syncope should be assessed thoroughly. Unfortunately, the initial presenting symptom of transplant vasculopathy may be acute myocardial infarction, heart failure, or even sudden death. Patients should be evaluated on an annual basis for the presence of transplant coronary vasculopathy in addition to when clinical suspicion warrants. Coronary angiography has been the main modality of invasive assessment, although it is insensitive. Recently, intracoronary ultrasound has been used in conjunction with angiography to detect the first evidence of transplant vasculopathy, manifested as thickening of the intimal layer of the vessel wall due to smooth muscle cell proliferation, which ultimately leads to luminal narrowing. Patients with evidence of vasculopathy should undergo functional evaluation with dobutamine echocardiography to document ischemic burden. Preventive measures include traditional coronary risk factor modification. Patients are started on statins early in the post-transplantation period and hypertension is treated aggressively using calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors. Because of their deleterious metabolic effects, steroids may be withdrawn under close surveillance for rejection. After transplant vasculopathy has developed, it is difficult to treat and options are limited. Patients with discrete luminal obstructions may undergo angioplasty, stenting, or coronary artery bypass. However, these procedures are palliative, and the only definitive therapy is retransplantation.
